ArticleRheumatology (Oxford, England)2026
Circulatory microRNA signature distinguishing rheumatoid arthritis and psoriatic arthritis.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesGene regulatory microRNAs (miRNAs) have emerged as promising biomarkers and therapeutic targets in autoimmunity pathology. This study examines circulatory miRNAs as cellular biomarkers that can distinguish rheumatoid arthritis (RA) from psoriatic arthritis (PsA) to evaluate the potential implications for disease pathogenesis.
methodsRA (n = 48) and PsA (n = 49) patients and healthy controls (HC) (n = 20) were recruited and serums obtained. Multiplex analysis of serum miRNAs was performed using the FirePlex miRNA Immunology-V2 panel (FirePlex Bioworks Inc.). DNA intelligent analysis (DIANA)-mirPath and STRING software were used to predict pathways targeted by the dysregulated miRNAs.
resultsSeven miRNAs, miR-126-3p, miR-29b-3p, miR-22-3p, miR-223-3p, miR-320a, let-7e-5p and let-7g-5p, were significantly elevated in RA serum compared with PsA (all P < 0.05), in addition to HC (all P < 0.05), with high sensitivity and specificity as determined by receiver operating characteristic curve analysis. Principal component analysis and biplot analysis demonstrated differential miRNA clustering between both disease states with a dominant skew towards three specific miRNAs in RA vs PsA: miR-29b-3p, miR-22-3p and miR-223-3p. DIANA analysis and STRING visualization of this miRNA signature identified downstream target pathways including phosphoinositide 3-kinase-AKT and FoxO signalling, all importantly associated with aspects of RA pathogenesis including angiogenesis, invasion and cell death.
conclusionThis study identified three key miRNAs demonstrating differential expression levels between RA and PsA, which potentially govern downstream inflammatory pathways regulating distinct disease mechanisms. Therefore, circulating miRNAs may be valuable as non-invasive diagnostic biomarkers that can distinguish RA from PsA and may additionally assist in elucidating differential disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.